Current Trials

Cardiovascular Disease

Cardiovascular Disease, or CVD, remains the number one cause of death in the US and the rest of the Western World.

Learn more about CVD


Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity

Familial Chylomicronemia Syndrome

Familial Chylomicronemia Syndrome (FCS) is rare genetic disorder that leads to extraordinarily high triglyceride (TG) levels.

Learn more about FCS

The APPROACH Extension Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx)

ISIS 304801-CS7, The APPROACH Open Label Extension Study Volanesorsen (ISIS 304801) An Open-Label Extension Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS).

Liver Diseases – NAFLD, NASH, and PBC

Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH) are common fatty liver diseases that afflict a relatively large percentage of the U.S. population. Risk factors include Type 2 Diabetes, hypertension, high triglycerides, high LDL cholesterol, being overweight and obesity.

Learn more about NAFLD and NASH

Primary Biliary Cholangitis (PBC) is a chronic liver disease resulting from the progressive destruction of the bile ducts in the liver.

Learn more about PBC


Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of NGM282 in Non-alcoholic Steatohepatitis (NASH)

CB8025-31735 PBC

Seladelpar in Subjects with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Urosodeoxycholic Acid (UDCA)


A Study of ISIS 703802 in Subjects with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Non-alcoholic Fatty Liver Disease

CB8025-21730 NASH

A Study to Evaluate Seladelpar in Subjects with Non-alcoholic Steatohepatitis (NASH)


Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily versus Placebo in Subjects with Non-alcoholic Steatohepatitis


A Study to Evaluate the Safety, Tolerability, and Efficacy of MSDC 0602K in Patients with NASH

Clinical Trial in Adults at High-Risk for Fatty Liver Disease

A cross-sectional study evaluating the prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in high-risk undiagnosed adults in South Florida.


Phase 2 Study of MGL-3196 in Patients with Non-Alcoholic Steatohepatitis (NASH).

Heart Failure

Two main types of congestive heart failure (CHF) exist: Reduced (HFrEF) and Preserved (HFpEF).

Learn more about heart failure (HFrEF and HFpEF)

EMPagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

A phase III randomized, double-blind placebo controlled trial to evaluate efficacy and safety of once daily empagliflozin 10 mg in patients with heart failure with preserved ejection fraction.

EMPagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

A phase III randomized, double-blind study to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF < 40%).

Familial Hypercholesterolemia

Two forms of familial hypercholesterolemia (FH) exist: Heterozygous (HeFH) and Homozygous (HoFH).

Learn more about HeFH and HoFH

R1500-CL-1719 HoFH

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia (HoFH)

EFC14643 HeFH

An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial Hypercholesterolemia


Study of Evinacumab (REGN1500) in Participants with Persistent Hypercholesterolemia


Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C in Subjects with Heterozygous Familial Hypercholesterolemia (HeFH)

R727-CL-1629 HoFH

Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia

R727-CL-1628 HoFH

Study in Participants ≥12 years of age with Homozygous Familial Hypercholesterolemia (HoFH)

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

AAV8-mediated low density lipoprotein receptor (LDLR) gene replacement in subjects with homozygous familial hypercholesterolemia (HoFH).

Hyperlipidemia / Hypercholesterolemia

Hyperlipidemia/Hypercholesterolemia (elevated lipids/cholesterol) represent the greatest population attributable risk for cardiovascular disease (CVD).

Learn more about Hyperlipidemia/Hypcholesterolemia


A Study with Bempedoic Acid plus Ezetimibe Fixed-Dose Combination (FDC) Study in Patients with Type 2
Diabetes and Elevated LDL-C

Protocol 20130287

A Study in Subjects with Type 2 Diabetes Mellitus with Hypercholesterolemia/Mixed Dyslipidemia


Cascade Screening for Awareness and Detection of familial hypercholesterolemia.

LOWER Registry

LOWER: Lomitapide observational worldwide evaluation registry. This registry is a multicentre, long-term, prospective, observational cohort study designed to evaluate the long term safety and effectiveness of lomitapide.


A 12-week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins (ROYAL-1).

GOULD Registry

Getting to an improved understanding of LDL-C and dyslipidemia management (GOULD): a registry of high cardiovascular risk patients in the United States.

ODYSSEY DM-Dyslipidemia Study

A randomized, open-label, parallel group study to evaluate the efficacy and safety of alirocumab versus usual care in patients with Type 2 Diabetes and mixed dyslipidemia at high cardiovascular risk with non-HDL- C not adequately controlled with maximally tolerated statin therapy.


Inclisiran for Participants with Atherosclerotic Cardiovascular Disease and Elevated Low-Density Lipoprotein Cholesterol


A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in patients with Treated with Maximally Tolerated Statin Therapy

1002-047 CLEAR Wisdom

Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients with Hyperlipidemia at High Cardiovascular Risk


Triple Therapy in Patients with Elevated LDL-C


Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 mg

1002-040 CLEAR Harmony

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients with Hyperlipidemia and High CV Risk


Hyperlipoproteinemia(a), or elevated Lp(a), is a common condition in the U.S. Elevated levels of Lp(a) are correlated with heart attack, stroke, and aortic stenosis (narrowing of the aortic valve).

Learn more about elevated Lp(a)

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients with Hyperlipoproteinemia(a) and Cardiovascular Disease

A randomized, double-blind, placebo-controlled, dose-ranging phase 2 study of ISIS 681257 administered subcutaneously to patients with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).


Hypertriglyceridemia (HTG) is a common condition in which TG, the major fat source we consume, is elevated in the blood.

Learn more about HTG

ISIS 678354-CS2

Study of ISIS 678354 (AKCEA-APOCIII-LR) in Patients with Hypertriglyceridemia and Established Cardiovascular Disease (CVD)


A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)


Outcomes Study to Assess Statin Residual risk reduction with EpaNova in high CV risk patients with Hypertriglyceridemia

Statin Intolerance

Statin medications are a type of lipid lowering therapy. Some individuals cannot tolerate statin medications because of a variety of side effects.

Learn more about Statin Intolerance

CLEAR Tranquility

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C.

CLEAR Outcomes

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant.

Type 2 Diabetes

Type 2 Diabetes, or Diabetes Mellitus, is a disorder related to the production or utilization of the pancreatic hormone, insulin.

Learn more about Type 2 Diabetes (Diabetes Mellitus)


Cardiovascular Inflammation Reduction Trial


Bexagliflozin Efficacy and Safety Trial


Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434